Results for percutaneous translation from English to Maltese

percutaneous
perkutaneja

percutaneous absorption
assorbiment perkutanju

percutaneous single dose
doża waħda perkutanji

acute percutaneous toxicity
tossiċità akuta mill-ġilda

percutaneous coronary intervention (pci)
intervent koronarju perkutanju (pci)

other routes (inhalation, percutaneous as appropriate)
rotot oħrajn (teħid tan-nifs, perkutanja kif xieraq)

chemical agents of known and dangerous percutaneous absorption.
aġenti kimiċi li l-assorbiment mill-ġilda huwa magħruf u perikoluż.

for patients undergoing angioplasty (percutaneous coronary intervention)
għal pazjenti li għaddejjin minn anġjografija (intervent koronarju perkutaneju)

inflammation can increase the percutaneous absorption of veterinary medicinal products.
l-infjammazzjoni tista’ żżid l-as orbiment minn ġol-ġilda ta’ prodotti mediċinali veterinarji.

an anticoagulant in patients undergoing percutaneous coronary intervention (pci).
antikoagulant f’ pazjenti sottoposti għal intervent koronarju perkutanju (pci – percutaneous coronary intervention).

the acute percutaneous toxicity of the active substance must always be reported.
it-tossiċità akuta perkutanja tas-sustanza attiva trid dejjem tiġi rrappurtata.

absorption, distribution and excretion studies - following both oral and percutaneous administration
studji dwar assorbiment, distribuzzjoni u eskrezjoni - wara amministrazzjoni kemm mill-ħalq kif ukoll perkutanja.

teratogenicity studies - rabbit and one rodent species, oral and when appropriate percutaneous
studji ta' teratoġeniċità - fenek u speċi waħda ta' rodenti , mill-ħalq u fejn xieraq perkutanji

or tacrolimus is not metabolised in human skin, indicating that there is no potential for percutaneous
to aw 4. 5 prodotti mediċinali oħra li ma jaqblux ma 'dan il- prodott u affarjiet oħra li jistgħu jibdlu l- effett farmaċewtiku tal- prodott

interactions with systemic drugs would be limited by the minimal percutaneous absorption of imiquimod cream.
dawn l- interazzjonijiet mal-mediċini sistemiċi jkunu limitati bl-assorbiment perkutaneju minimu tal-krema imiquimod.

when applied topically, systemic overdosage with imiquimod cream is unlikely due to minimal percutaneous absorption.
meta applikat topikament, doża sistematika eċċessiva bil-krema imiquimod mhux probabbli sseħħ minħabba assorbenza perkutanea minima.

in case of significant percutaneous absorption, systemic effects shall be considered and noael shall be assessed.
fil-każ ta’ assorbiment perkutaneju sinifikanti, għandhom jitqiesu l-effetti sistemiċi u n-noael għandu jiġi vvalutat.

the extent of percutaneous absorption of topical medications is determined by many factors including the integrity of the epidermal barrier.
il-grad ta’ as orbiment minn ġol-ġilda ta’ mediċini topiċi hu stabbilit minn ħafna fatturi li jinkludu l-integrità tal-barriera epidermali.

the pharmacokinetic properties of bivalirudin have been evaluated and found to be linear in patients undergoing percutaneous coronary intervention and in patients with acs.
il-kwalitajiet farmakokinetiċi ta’ bivalirudin ġew evalwati u nstabu li huma lineari f’pazjenti sottoposti għal intervent koronarju perkutanju u f’pazjenti b’acs

e if a patient is to undergo percutaneous coronary intervention (pci), unfractionated heparin (ufh) as
jekk għandu jsir intervent koronarju minn ġol- ġilda (pci) fuq pazjent, għandha tiġi amministrata l - eparina mhux frazzjonata (ufh) waqt il- pci, skond il- prattika lokali u għandu jiġi kkunsidrat ir- riskju